Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, starts the discussion of the Enhancing Oncology Model by asking panelists to reflect on the need for CMS to provide a successor to the Oncology Care Model (OCM). Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology; Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance; and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agree that practices that had invested in practice transformation under the OCM would have been extremely disappointed if there had been no successor to the OCM.
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal
July 15th 2025CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
Read More